Bio

Clinical Focus


  • Cancer > Sarcoma
  • Cancer > Thoracic Oncology
  • Thoracic Surgery
  • Cardiothoracic Surgery

Academic Appointments


Professional Education


  • Fellowship:Brigham and Women's Hospital Harvard Medical School (2012) MA
  • Residency:Brigham and Women's Hospital Harvard Medical School (2010) MA
  • Internship:Brigham and Women's Hospital Harvard Medical School (2004) MA
  • Medical Education:Weill Cornell Medical College (2003) NY

Teaching

2013-14 Courses


Postdoctoral Advisees


Publications

Journal Articles


  • Clinical indications and results after chest wall resection for recurrent mesothelioma. journal of thoracic and cardiovascular surgery Burt, B. M., Ali, S. O., DaSilva, M. C., Yeap, B. Y., Richards, W. G., Baldini, E. H., Sugarbaker, D. J. 2013; 146 (6): 1373-1380

    Abstract

    The ipsilateral hemithorax is the most common site of recurrence after surgical resection for malignant pleural mesothelioma. Salvage treatment has generally been ineffective. We reviewed the outcomes after resection of isolated ipsilateral chest recurrence after cytoreductive surgery in patients with malignant pleural mesothelioma.Patients with malignant pleural mesothelioma who underwent initial surgical resection at our institution from 1988 to 2011 and were subsequently treated for localized recurrence with an additional chest resection were identified and their data retrospectively reviewed.A total of 1142 patients underwent either extrapleural pneumonectomy (n = 794) or pleurectomy/decortication (n = 348). Of the patients who returned for follow-up, 47 (4.1%) had chest wall recurrence amenable to resection. The location of recurrence was predominantly incisional (49%) and/or costophrenic (38%). The median time to recurrence after either extrapleural pneumonectomy or pleurectomy/decortication was 16.1 months (range, 2.7-58.2). No 30-day mortality was found for chest wall resection, and the median length of stay in the hospital was 3 days (range, 0-12). The median overall survival duration after chest wall resection correlated positively with the time to recurrence (epithelial: median, 8.9, 17.2, and 35.8 months for a time to recurrence of <12, 12 to <24, and ≥24 months, respectively; biphasic: median, 2.7 and 15.9 months for a time to recurrence of <10 and ≥10 months, respectively).Chest wall resection is a safe and effective therapeutic option in the management of localized chest wall recurrence of malignant pleural mesothelioma. The time to recurrence appears to be predictive of the expected survival benefit in both epithelial and biphasic malignant pleural mesothelioma.

    View details for DOI 10.1016/j.jtcvs.2013.07.012

    View details for PubMedID 24113019

  • A Dominant Adenocarcinoma With Multifocal Ground Glass Lesions Does Not Behave as Advanced Disease ANNALS OF THORACIC SURGERY Gu, B., Burt, B. M., Merritt, R. E., Stephanie, S., Nair, V., Hoang, C. D., Shrager, J. B. 2013; 96 (2): 411-418

    Abstract

    Invasive lung adenocarcinomas increasingly present with synchronous, multifocal, in situ lesions that appear as ground glass opacities (GGOs). The optimal approach in this circumstance (often nonsmokers) remains unclear. We evaluated a general strategy of anatomic resection of the dominant tumor (DT) and wedge resection of accessible ipsilateral GGOs.This is a retrospective review of 39 patients with suspected multifocal in situ adenocarcinomas and 1 DT in a predominantly Caucasian population. Mean follow-up is 30.7 months.Forty-nine percent of patients had no or minimal smoking history; 21% were Asian. The resected DT was pathologically "bronchioloalveolar carcinoma" (26%), minimally invasive adenocarcinoma (5%), adenocarcinoma with bronchioloalveolar features (41%), or moderate well-differentiated adenocarcinoma (28%). The p stage of the DT was IA in 20, IB in 15, and IIA in 4, with mean diameter of 2.6 cm. Thirty-two patients (82%) underwent anatomic resection of the DT; 7 (18%) underwent wedge resection. The mean number of GGOs present initially was 2.7 (range, 1 to 7) with a 5.2-mm mean diameter. An unresected nodule increased in size during follow-up in only 9 patients (23%). The mean diameter growth among these was 3.2 mm, with mean doubling time of 49 months. New GGOs (range, 1 to 8) developed in 16 patients (41%), all of which remained at 7 mm or less. Distant metastasis developed in 2 patients (5.2%); only 1 patient has required intervention for progression of a GGO. The overall survival is 100%.Patients with limited, multifocal, in situ adenocarcinomas and a clinical N0 DT enjoy prolonged survival with generally anatomic resection of the DT and wedge resection of accessible GGOs. These patients should not be considered to harbor T4 or M1a disease.

    View details for DOI 10.1016/j.athoracsur.2013.04.048

    View details for Web of Science ID 000323177800015

    View details for PubMedID 23806231

Stanford Medicine Resources: